Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 10/20 | 0.53 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | CALML3 | P27482 | 6/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL463294 | 0.94 | MAOA (0.60) | MAOACYP2E1MAOBCALML3CYP2C19 | |
| SCHEMBL463290 | 0.85 | MAOA (0.52) | MAOACYP2E1MAOBCALML3CYP2C19 | |
| SCHEMBL463398 | 0.83 | MAOA (0.60) | MAOACYP2E1MAOBCALML3CYP2C19 | |
| SCHEMBL12964763 | 0.83 | MAOA (0.61) | MAOACYP2E1MAOBCALML3CYP2C19 | |
| SCHEMBL15830322 | 0.83 | MAOA (0.61) | MAOACYP2E1MAOBCALML3CYP2C19 | |
| SCHEMBL463295 | 0.83 | MAOA (0.60) | MAOACYP2E1MAOBCALML3CYP2C19 | |
| SCHEMBL463586 | 0.82 | MAOA (0.48) | MAOACYP2E1 | |
| SCHEMBL463412 | 0.82 | CYP2E1 (0.51) | MAOACYP2E1MAOBCALML3CYP2C19 | |
| SCHEMBL15830205 | 0.81 | MAOA (0.58) | MAOACYP2E1MAOBCALML3CYP2C19 | |
| SCHEMBL12964777 | 0.81 | MAOA (0.58) | MAOACYP2E1MAOBCALML3CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012033952-A1 | 3 - PHENYL- 2 -OXO- 1, 3 -OXAZOLIDINES FOR TREATMENT OF BACTERIAL INFECTIONS | MICURX PHARMACEUTICALS, INC. (KY) | 2012-03-15 | — | — | WO | disclosed |